Response Biomedical - Zukunftswert
Seite 28 von 41 Neuester Beitrag: 18.06.10 00:04 | ||||
Eröffnet am: | 13.08.09 12:18 | von: fuerza_hercu. | Anzahl Beiträge: | 2.008 |
Neuester Beitrag: | 18.06.10 00:04 | von: Benull | Leser gesamt: | 111.730 |
Forum: | Hot-Stocks | Leser heute: | 47 | |
Bewertet mit: | ||||
Seite: < 1 | ... | 25 | 26 | 27 | | 29 | 30 | 31 | ... 41 > |
Imho sind die in D gehandelten Stückzahlen lächerlich und der Spread ist grausam.
Sprich alles GEGEN ein Invest in RPB.................tja hinterher ist man immer schlauer.
Decon
leute ich sag euch: wir kommen hier nicht mehr raus....das teil ist tot...kein handel, kein interessenten...was für ein dreckslappen....ich dachte erst ein totsicheres Invest. Jetzt fallen die Grippeschutzimpfungen auch noch weg...
So,
Kommt gut ins neue Jahr!
leg ich nochmal nach um meinen EK in eine bessere Ausgangsposition zu bekommen, jedenfalls gilt hier das Lied:
Kein Schwein ruft mich an, keine Sau interessiert sich für mich...
Zumindest gehts anscheinend mit der Bude Stück für Stück nach oben, braucht man wohl einen längeren Atem... solange 3M (ca. 11%), Beutel und Goodman (ca. 19%) noch Hauptaktionäre sind fühl ich mich doch relativ save...
Er ist ebenfalls BOD bei CTQ
Hier ist nun weiteres zum Nachlesen
http://www.marketwire.com/press-release/...s-Inc-TSX-CTQ-1095925.html
Vielleicht hat er ja jetzt dann nun etwas überflüssiges Geld und kauft vllt ein paar RBM nach ;-)
Ist die Bude pleite ??
Decon
VANCOUVER--(BUSINESS WIRE)--Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced today that the Company has received a Notice of Allowance from the European Patent Office for the patent entitled “Sensitive Immunochromatographic Assay”, referred to as the “Fong Patent”. This critical patent protects key aspects of Response Biomedical’s lateral flow immunoassays conducted with the proprietary RAMP® testing platform.
“The ‘Fong Patent’ is a pivotal piece of our intellectual property portfolio and we are very pleased with the European Patent Office’s (EPO) decision to grant our claims in support of our technology platform,” said S. Wayne Kay, Chief Executive Officer. “Our market expansion plans, in conjunction with our key partners, will have significant focus on the European Union. We expect to see RAMP® continue to set new performance standards in rapid diagnostic testing by providing lab quality information in minutes.”
The Fong Patent describes various methods to improve assay performance through the correction of intrinsic variability in lateral flow assays, which provides more precise results than typical lateral flow methods. This patent has been issued in the United States and Australia and is pending in China, Hong Kong, Japan and Canada. Recently the Company announced it had received further continuation of the Fong Patent from the United States Patent and Trademark Office for the competitive claims, significantly expanding the U.S. intellectual property to allow coverage for small molecules. The Company is currently seeking additional partners to develop products covered under its portfolio of patent protection
Tampa, FL - Pilgrim Software, Inc., a world-leading provider of Enterprise Compliance and Quality Management (ECQM) software solutions, recently announced that Response Biomedical, a producer of rapid on-site diagnostic tests, has gone live with Pilgrim's solution for complaints management to help expedite complaint handling while ensuring ongoing regulatory compliance.
Pilgrim's Complaints Management solution provides Response Biomedical with a single source data center for tracking and managing all complaints within its facilities. It enables rapid complaint resolution through its e-mail notifications, and tracking and escalation capabilities; improves the management of customer communication; and, ensures regulatory and industry compliance.
Response chose to automate its complaints processing and eliminate manual systems allowing for easier tracking and trending analyses. It turned to Pilgrim's On Demand solution to help reduce the time required of its limited in-house IT staff to conduct a full implementation, including validation to comply with 21 CFR Part 11 requirements.
"We saw Pilgrim's SAS 70-certified hosted model as the right solution for our needs," said Marcia Zucker, Ph.D., Response Biomedical's director of Clinical Support. "We recently moved into a new facility, and have limited service space for servers, so choosing to implement Pilgrim's solution on-demand frees up both hardware requirements and allows our IT team more time to address other key projects."
Pilgrim's Complaints Management solution will enable Response to more efficiently manage customer complaints and document responses to incidents. Because of its inherent scalability, the solution also can be expanded should Response add users, and it can be easily integrated with other automated quality and compliance management solutions. Even with expansion and integration, the On Demand model helps keep the company's IT costs to a minimum, allowing it to increase its overall revenues.
"Our Complaints Management solution is the right software for life sciences companies like Response Biomedical because it takes the worry out of their complaint handling and overall quality assurance efforts, and enables them to redirect their resources toward other challenges facing their industry," said Prashanth Rajendran, Pilgrim's Chief Operating Officer. "Implementing it on-demand further expedites the ROI of the solution."
About Response Biomedical
Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP® Platform for clinical and environmental applications. RAMP® represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point-of-care testing and laboratory use. RAMP® clinical tests are commercially available for the early detection of heart attack and congestive heart failure. In late 2006, the Company formed a strategic alliance with 3M Company to commercialize rapid infectious disease tests. In the non-clinical market, RAMP® Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development. Response has achieved CE Marking and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000.
About Pilgrim Software, Inc.
Pilgrim Software, Inc. is a world-leading provider of Enterprise Compliance and Quality Management solutions for global organizations. Named 2007 & 2008 North American Enterprise Compliance & Quality Management Company of the Year by Frost & Sullivan, Pilgrim helps organizations manage industry and regulatory compliance, reduce manufacturing costs and improve customer satisfaction.
http://www.pharmaceuticalonline.com/article.mvc/...0001?VNETCOOKIE=NO
der boden scheint erreicht zu sein. Bei dieser Nummer will ich jedoch nicht zu laut schreien. Das ist das größte Schrottpapier, was ich jemals gekauft habe.....Aber auch die Apple Aktie ist mal klein angefangen. ;-)
.............und der Kurs stagniert oder ist rückläufig. Das Paket ist zusammen normalerweise für einen 3-stelligen Kurssprung gut und bei unserer RBM passiert nix ! Das Ding fordert so langsam meinen Ehrgeiz heraus. Und dann bleib ich drin bis mir n grauer Bart wächst. Weiß denn nicht Iiiiiiirgendjemand was da los ist ?
Danke für jede auch noch so kleine plausible Antwort.
Decon